Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.

International journal of molecular sciences·2026

Same author

The Role of Dipeptidyl Peptidase Inhibitors in Pulmonary Diseases.

Biomedicines·2026

Same author

Persistence of alveolar fibroblast-derived ADAMTS4+ cells in a preclinical model of delayed pulmonary fibrosis resolution.

Nature communications·2026

Same author

Timing of Redox Imbalances in Cardiac Surgery.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

Same author

Adherence and Effectiveness of Positive Airways Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA) Patients Suffering from Mental Disorders.

Healthcare (Basel, Switzerland)·2026

Same author

[Mechanisms of dyspnea].

Pneumologie (Stuttgart, Germany)·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Lung Cancer and Interstitial Lung Diseases.

Fotios Drakopanagiotakis¹, Ekaterina Krauss^2,3, Ira Michailidou⁴

¹Department of Pneumonology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.

|August 29, 2024

Summary

Lung cancer and interstitial lung disease (ILD) share risk factors and complicate treatment. Further research is needed to improve outcomes for patients with both lung cancer and ILD.

Keywords:

IPF interstitial lung disease lung cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jun 14, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Area of Science:

Oncology
Pulmonology
Radiology

Background:

Lung cancer remains a leading cause of cancer death globally.
Interstitial lung disease (ILD) and lung cancer share common risk factors, including smoking and genetic predispositions.
The co-occurrence of ILD complicates lung cancer diagnosis and management, increasing risks of treatment-related toxicities.

Purpose of the Study:

To explore the complex interplay between lung cancer and ILD.
To highlight diagnostic and therapeutic challenges in managing patients with both conditions.
To emphasize the need for improved management strategies and evidence-based treatments.

Main Methods:

Review of existing literature on lung cancer and ILD.
Analysis of shared risk factors and their impact.
Discussion of diagnostic challenges, including radiological interpretation.
Examination of treatment-related toxicities and limited evidence-based options.

Main Results:

ILD presence complicates lung cancer diagnosis and treatment.
Patients with ILD are more susceptible to treatment toxicities like pneumonitis and acute exacerbations.
Limited evidence from large trials exists for optimal treatment strategies.
The role of antifibrotic therapy in preventing pulmonary toxicity is still under investigation.

Conclusions:

The interplay between lung cancer and ILD presents significant clinical challenges.
There is a critical need for more robust clinical trials to guide treatment decisions.
Emerging diagnostic tools, biomarkers, and personalized medicine are crucial for improving outcomes in this patient population.